COVİD-19 Tanısıyla Tedavi Edilen Hastalarda Klinik Deneyimler

Öz

Amaç: Tüm dünyada COVID-19 enfeksiyonunu etkileyebilecek spesifik bir antiviral ve immünomodülatör tedavi yöntemi bulunamamıştır ve araştırmalar devam etmektedir. Amacımız kliniğimizde tedavi gören COVID-19 hastalarındaki klinik deneyimlerimizi paylaşmaktır. Gereç ve Yöntem: 11 Mart – 31 Mayıs 2020 tarihleri arasında semptomları COVID-19 ile uyumlu olan ve mikrobiyolojik bulguları/ tomografi bulguları uyumlu olan hastalar çalışmaya alındı. Bulgular: Çalışmaya dahil edilen 180 hasta arasında; 45 (%25.0) hastaya HCQ tedavisi sonrası favipiravir tedavisi eklendiği saptandı. Tedavi grupları arasında; yaş, meslek, oksijen satürasyonu, diabetes mellitus, hipertansiyon ve akciğer hastalığı varlığı ve BT bulguları arasındaki ilişki bu idi. (p <0.05). Sonuç: Hasta gruplarında; 65 yaş ve üzeri, komorbiditesi olan, başvuruda yaygın BT tutulumu olan, Sat O2≤94 olan hastalarda favipiravir tedavisine geçilmesi ve yanıt alınması tedavi seçiminde belirleyici olabilir.

Anahtar Kelimeler

• Hydroxychloroquine
• tedavi
• Favipiravir
• Covid-19

Clinical Experiences in Patients Treated with the Diagnosis of COVID-19

Öz

Objective: All over the world, a specific antiviral and immunomodulatory treatment method that can affect COVID-19 infection has not been found, and research is ongoing. Our goal is to share our clinical experience in patients receiving in patient treatment in our clinic. Materials and Methods: Patients whose symptoms were compatible with COVID-19 and whose microbiological findings and/or tomography findings were compatible between March 11 and May 31, 2020 were included in the study. Results: Among 180 patients included in the study; It was found that favipiravir treatment was added to 45 (25.0%) patients after HCQ treatment. A significant difference was found between treatment groups concerning; age, occupation, oxygen saturation, presence of diabetes mellitus, hypertansion and lung disease, and CT findings (p <0.05). Conclusion: In patient groups; Switching to favipiravir treatment and getting a response in patients aged 65 and over, with comorbidities, widespread CT involvement at admission, and Sat O2≤94 may be predictive in treatment selection.

Anahtar Kelimeler

• Covid-19
• Favipiravir
• Hydroxychloroquine
• treatment

Kaynakça

1. Bahceci I, Yildiz I E, Duran O F, Soztanaci US, KirdiHarbawi Z, Senol FF, et al . Secondary Bacterial Infection Rates Among Patients With COVID-19. Cureus. 2022;14(2):e22363. doi:10.7759/cureus.22363.
2. Bahceci I, Senol FF. Post-vaccination COVID-19 positivity and clinical situation analysis in healthcare professionals. Annals of Clinical and Analytical Medicine. 2022 13(9), 959-962. doı: 10.4328/ACAM.21139
3. Bahçeci I, Yıldız S, İbik YE, Duran OF, Arslan N, Sahin K. Determination of HBsAg, Anti-HCV and Anti-HIV Reactivity in Covid-19 Patients Evaluation. Journal of Immunology and Clinical Microbiology. 2022; 7(3), 51-57.
4. Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, et al. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants. International journal of antimicrobial agents. 2020:106144. doi: 10.1016/j.ijantimicag.2020.106144
5. Çakırca D, Bal T. Relationship between COVID-19 infection and ABO and Rh blood group systems. Cukurova Medical Journal. 2022 : 1485- 1491. doi: 10.17826/cumj.1134928
6. Şenol FF, Bahçeci I, Arslan N, Aytaç Ö, Öner P, Aşcı Toraman Z. Comparison of respiratory tract pathogens and antibiotic susceptibility profiles of patients diagnosed with COVID-19 with pre-COVID-19. Journal of Health Sciences and Medicine. 2022; 5(2): 510-516. doi.org/10.32322/jhsm.1010249
7. Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates. 2020; 53:1 00719. doi: 10.1016/j.drup.2020.100719.
8. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome. 2020;14: 241-6. doi: 10.1016/j.dsx.2020.03.011

9. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020;57: 279-83. doi: 10.1016/j.jcrc.2020.03.005
10. The Republic of Turkey Ministry of Health Directorate General of Public Health. Müdürlüğü SBHSG. COVID-19 (SARS-CoV-2 Infection) Adult Patient Treatment. Ankara. 2 August 2020.
11. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature reviews Rheumatology. 2020; 16:155-66.
12. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020; 30:269-71.
13. Kaptein SJ, Jacobs S, Langendries L, Seldeslachts L, ter Horst S, Liesenborghs L, et al. Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine. Bio R xiv. 2020:2020.06.19.159053. doi: https://doi.org/10.1101/2020.06.19.159053
14. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020; 56:105949. doi: 10.1016/j.ijantimicag.2020.105949
15. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020. DOI: 10.1016/j.eng.2020.03.007
16. Du Y-X, Chen X-P. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clinical Pharmacology & Therapeutics. 2020; 108: 242-7. doi: 10.1002/cpt.1844
17. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020. doi:10.1101/2020.03.17.20037432